Evidence map›Paper›PMID 32274633›Full record

SynthesisInternational journal of clinical pharmacy2020

Effects of generic exchange of solid oral dosage forms in neurological disorders: a systematic review.

Johanna Weitzel, Susanne Erzkamp, Klaus Langer, Olaf Rose

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in International journal of clinical pharmacy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Johanna WeitzelDepartment of Pharmaceutical Technology and Biopharmaceutics, Westfälische Wilhelms-University Muenster, Corrensstr. 48, 48149, Muenster, Germany.ORCID http://orcid.org/0000-0002-1453-4113
Susanne ErzkampImpac2t Research, Maximilianstr. 31-33, 48147, Muenster, Germany.ORCID http://orcid.org/0000-0003-2416-0546
Klaus LangerDepartment of Pharmaceutical Technology and Biopharmaceutics, Westfälische Wilhelms-University Muenster, Corrensstr. 48, 48149, Muenster, Germany.ORCID http://orcid.org/0000-0002-0203-7478
Olaf RoseImpac2t Research, Maximilianstr. 31-33, 48147, Muenster, Germany. rose@elefantenapo.de.ORCID http://orcid.org/0000-0003-1681-4909
University of Münster · DEAmerican Association of Colleges of Pharmacy · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Generic drug exchange is common practice in most healthcare systems. While generics certainly contribute to economic savings, the altered drug formulation might be associated with potential therapeutic problems. Given the narrow therapeutic windows in neurologic indications, any detrimental effect on the therapy can lead to significant consequences. Aim of the review This review aims to investigate potential problems related to a switch from brand-name to generic or from generic to generic drug products in patients with neurologic diseases. Method The review was conducted following the PICO framework and the PRISMA guidelines. MEDLINE and Scopus databases were searched for articles published in English and German language between January 1, 1995 and October 17, 2018. Studies included in this review were randomized controlled studies, reviews, systematic reviews, overviews, cohort studies and case-control studies. Studies excluded were letters, comments, authors view, congress or seminar papers and studies with a focus on economic impact or costs. Results were synthesized qualitatively. The primary outcomes were pharmacokinetic parameters such as the area under the curve (AUC), the peak serum concentration (c

Indexed as

Area Under CurveCentral Nervous System AgentsDrugs, GenericHumansMetabolic Clearance RateNervous System DiseasesTherapeutic EquivalencyCentral Nervous System AgentsDrugs, GenericAntiepilepticsDrug-related problemGeneric substitutionNeurologyParkinson’s diseasePharmacotherapySystematic review

Identifiers

PMID32274633
OpenAlexW3015317198

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.